Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 49, No. 3, 2003   

Free Abstract     Article (Fulltext)     Article (PDF 85 KB)     

Original Paper

Comparative Single-Dose Pharmacokinetics of Clonazepam following Intravenous, Intramuscular and Oral Administration to Healthy Volunteers
C. Crevoisiera,b, M.C. Delislec, I. Josepha, G. Folettic

aDepartment of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, Basel,
bClinical Pharmacology Services, Dornach, and
cInstitution of Lavigny, Neurological and Educational Center, Lavigny, Switzerland

Address of Corresponding Author

Eur Neurol 2003;49:173-177 (DOI: 10.1159/000069089)


 goto top of page Key Words

  • Clonazepam
  • Pharmacokinetics
  • Bioavailability
  • Intravenous
  • Intramuscular
  • Oral

 goto top of page Abstract

The objective was to assess the single-dose pharmacokinetics of clonazepam following i.m., p.o. and i.v. administration. In an open-label, three-way crossover study, 12 healthy volunteers were randomized to receive a single dose of 2 mg clonazepam either by the i.m., p.o. or i.v. route. Serial blood samples were collected up to 120 h after drug administration. Plasma concentrations of clonazepam were determined by electron-capture gas-liquid chromatography. The absorption rates of clonazepam after i.m. and p.o. administration of clonazepam were significantly different from each other, as reflected by the respective mean values of maximum plasma concentration (Cmax 11.0 vs. 14.9 ng·ml-1) and time to reach maximum concentration (tmax 3.1 vs. 1.7 h). Secondary plasma peaks of clonazepam were observed in 9 volunteers after i.m. injection (Cmax 9.9 ng·ml-1; tmax 10.4 h). A comparison of the area under the plasma concentration-time curves (AUC) shows that the i.m. route is equivalent to the oral route (AUC0-infin 620 vs. 561 ng·h·ml-1). Clonazepam was almost completely absorbed after i.m. and p.o. administration, as shown by the mean absolute bioavailability of 93 and 90%, respectively. No significant differences existed between the elimination half-lives (i.v. 38.0 h; i.m. 43.6 h; p.o. 39.0 h). The average clearance and volume of distribution (VZ) were 55 ml·min-1 and 180 liters, respectively. In conclusion, the observed differences in Cmax and tmax after i.m. and p.o. administration were consistent with a slower absorption rate of clonazepam after i.m. injection. The systemic exposure to clonazepam was not affected by the route of extravascular administration. Statistical evaluation of these kinetic data showed differences in the absorption rate, so that clonazepam given by the i.m. route is not bioequivalent to the oral route. On the basis of the results of this study, we would recommend the same i.m. and p.o. dose in epileptic patients, but therapeutic response would be expected to be less predictable and to occur later in the case of i.m. administration.

Copyright © 2003 S. Karger AG, Basel


 goto top of page Author Contacts

Dr. C. Crevoisier
Clinical Pharmacology Services
Spitalweg 17
CH-4143 Dornach (Switzerland)
Tel./Fax +41 61 701 3946, E-Mail ch.crevoisier@intergga.ch


 goto top of page Article Information

Received: July 2, 2002
Accepted: November 20, 2002
Number of Print Pages : 5
Number of Figures : 1, Number of Tables : 2, Number of References : 18

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 12646763)
Download Citation



This journal is part of the first subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues

Case Reports in Neurology


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.




copyright  © 2009 S. Karger AG, Basel